Chronic Obstructive Pulmonary DiseaseDACOTANCT01285167
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
An observational study of Chronic Obstructive Pulmonary Disease, run by AstraZeneca at 605 sites in Germany.
Trial summary
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease
- What is being tested?
- Daxas
- Type of treatment
- Pill or oral medicine
- How many people
- 3,645 participants
- Where
- 605 sitesGermany
- Study dates
- Aug 2010to Feb 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients diagnosed with severe COPD.
Main Inclusion Criteria:
- severe COPD
Main Exclusion Criteria:
- Child pugh (classified B and C)
Trial locations and contacts
605 sites in 1 country.
300 sites in 1 country
Germany300 sites
Nycomed Deutschland GmbH
Ahlen, 59227
Nycomed Deutschland GmbH
Ahlen, 59229
Nycomed Deutschland GmbH
Allendorf, 35108
Nycomed Deutschland GmbH
Allersberg, 90584
Nycomed Deutschland GmbH
Alpenrod, 57642
Nycomed Deutschland GmbH
Altena, 58762
Nycomed Deutschland GmbH
Altenburg, 04600
Nycomed Deutschland GmbH
Alzenau in Unterfranken, 63755
Nycomed Deutschland GmbH
Alzey, 55232
Nycomed Deutschland GmbH
Amberg, 92224
Nycomed Deutschland GmbH
Anklam, 17389
Nycomed Deutschland GmbH
Annaberg-Buchholz, 09456
Nycomed Deutschland GmbH
Arnsberg, 59821
Nycomed Deutschland GmbH
Aschaffenburg, 63739
Nycomed Deutschland GmbH
Aschaffenburg, 63743
Nycomed Deutschland GmbH
Attendorn, 57439
Nycomed Deutschland GmbH
Attenkirchen, 85395
Nycomed Deutschland GmbH
Auerbach, 08209
Nycomed Deutschland GmbH
Augsburg, 86150
Nycomed Deutschland GmbH
Augsburg, 86156
Nycomed Deutschland GmbH
Backnang, 71522
Nycomed Deutschland GmbH
Bad Doberan, 18209
Nycomed Deutschland GmbH
Bad Endorf, 83093
Nycomed Deutschland GmbH
Bad Essen, 49152
Nycomed Deutschland GmbH
Bad Freienwalde, 16259
Nycomed Deutschland GmbH
Bad Füssing, 94072
Nycomed Deutschland GmbH
Bad Honnef, 53604
Nycomed Deutschland GmbH
Bad Langensalza, 99947
Nycomed Deutschland GmbH
Bad Lippspringe, 33175
Nycomed Deutschland GmbH
Bad Reichenhall, 83435
Nycomed Deutschland GmbH
Bad Salzuflen, 32105
Nycomed Deutschland GmbH
Bad Salzuflen, 32108
Nycomed Deutschland GmbH
Bad Salzungen, 36433
Nycomed Deutschland GmbH
Bad Soden, 65812
Nycomed Deutschland GmbH
Bad Soden-Salmünster, 63628
Nycomed Deutschland GmbH
Bad Tennstedt, 99955
Nycomed Deutschland GmbH
Bad Wörishofen, 86825
Nycomed Deutschland GmbH
Badel, 39624
Nycomed Deutschland GmbH
Baden-Baden, 76530
Nycomed Deutschland GmbH
Bamberg, 96047
Nycomed Deutschland GmbH
Bamberg, 96049
Nycomed Deutschland GmbH
Bargteheide, 22941
Nycomed Deutschland GmbH
Baunatal, 34225
Nycomed Deutschland GmbH
Bausendorf, 54538
Nycomed Deutschland GmbH
Bautzen, 02625
Nycomed Deutschland GmbH
Beelitz, 14547
Nycomed Deutschland GmbH
Bensheim, 64625
Nycomed Deutschland GmbH
Bergisch Gladbach, 51429
Nycomed Deutschland GmbH
Bergisch Gladbach, 51465
Nycomed Deutschland GmbH
Bergkamen, 59192
Nycomed Deutschland GmbH
Bergneustadt, 51702
Nycomed Deutschland GmbH
Berlin, 10117
Nycomed Deutschland GmbH
Berlin, 10247
Nycomed Deutschland GmbH
Berlin, 10318
Nycomed Deutschland GmbH
Berlin, 10365
Nycomed Deutschland GmbH
Berlin, 10367
Nycomed Deutschland GmbH
Berlin, 10559
Nycomed Deutschland GmbH
Berlin, 10625
Nycomed Deutschland GmbH
Berlin, 10627
Nycomed Deutschland GmbH
Berlin, 10711
Nycomed Deutschland GmbH
Berlin, 10717
Nycomed Deutschland GmbH
Berlin, 10789
Nycomed Deutschland GmbH
Berlin, 10961
Nycomed Deutschland GmbH
Berlin, 12043
Nycomed Deutschland GmbH
Berlin, 12099
Nycomed Deutschland GmbH
Berlin, 12157
Nycomed Deutschland GmbH
Berlin, 12165
Nycomed Deutschland GmbH
Berlin, 12203
Nycomed Deutschland GmbH
Berlin, 12279
Nycomed Deutschland GmbH
Berlin, 12555
Nycomed Deutschland GmbH
Berlin, 12627
Nycomed Deutschland GmbH
Berlin, 12679
Nycomed Deutschland GmbH
Berlin, 12687
Nycomed Deutschland GmbH
Berlin, 13055
Nycomed Deutschland GmbH
Berlin, 13057
Nycomed Deutschland GmbH
Berlin, 13156
Nycomed Deutschland GmbH
Berlin, 13187
Nycomed Deutschland GmbH
Berlin, 13353
Nycomed Deutschland GmbH
Berlin, 13405
Nycomed Deutschland GmbH
Berlin, 13465
Nycomed Deutschland GmbH
Berlin, 13507
Nycomed Deutschland GmbH
Berlin, 13581
Nycomed Deutschland GmbH
Berlin, 14052
Nycomed Deutschland GmbH
Berlin, 14059
Nycomed Deutschland GmbH
Bernau, 16321
Nycomed Deutschland GmbH
Biedenkopf, 35216
Nycomed Deutschland GmbH
Bielefeld, 33647
Nycomed Deutschland GmbH
Bietigheim-Bissingen, 74321
Nycomed Deutschland GmbH
Bitterfeld-Wolfen, 06749
Nycomed Deutschland GmbH
Blankenhain, 99444
Nycomed Deutschland GmbH
Bochum, 44866
Nycomed Deutschland GmbH
Bochum, 44879
Nycomed Deutschland GmbH
Bondorf, 71149
Nycomed Deutschland GmbH
Bonn, 53111
Nycomed Deutschland GmbH
Bonn, 53113
Nycomed Deutschland GmbH
Bonn, 53119
Nycomed Deutschland GmbH
Bonn, 53123
Nycomed Deutschland GmbH
Bonn, 53225
Nycomed Deutschland GmbH
Bonndorf, 79848
Nycomed Deutschland GmbH
Bottrop, 46236
Nycomed Deutschland GmbH
Bottrop, 46240
Nycomed Deutschland GmbH
Bovenden, 37120
Nycomed Deutschland GmbH
Braunfels, 35619
Nycomed Deutschland GmbH
Braunsbedra, 06242
Nycomed Deutschland GmbH
Braunschweig, 38100
Nycomed Deutschland GmbH
Braunschweig, 38106
Nycomed Deutschland GmbH
Bredstedt, 25821
Nycomed Deutschland GmbH
Breitengüßbach, 96149
Nycomed Deutschland GmbH
Bremerhaven, 27570
Nycomed Deutschland GmbH
Bremerhaven, 27578
Nycomed Deutschland GmbH
Bremerhaven, 27580
Nycomed Deutschland GmbH
Brilon, 59929
Nycomed Deutschland GmbH
Bruchsal, 76646
Nycomed Deutschland GmbH
Brunsbüttel, 25541
Nycomed Deutschland GmbH
Büchen, 21514
Nycomed Deutschland GmbH
Buckow, 15377
Nycomed Deutschland GmbH
Büddenstedt, 38372
Nycomed Deutschland GmbH
Bünde, 26831
Nycomed Deutschland GmbH
Bünde, 32257
Nycomed Deutschland GmbH
Burgau, 89331
Nycomed Deutschland GmbH
Burgstädt, 09217
Nycomed Deutschland GmbH
Burgwedel, 30938
Nycomed Deutschland GmbH
Callenberg, 09337
Nycomed Deutschland GmbH
Camburg, 07774
Nycomed Deutschland GmbH
Celle, 29221
Nycomed Deutschland GmbH
Chemnitz, 09126
Nycomed Deutschland GmbH
Coburg, 96450
Nycomed Deutschland GmbH
Cologne, 50672
Nycomed Deutschland GmbH
Cologne, 50733
Nycomed Deutschland GmbH
Cologne, 50825
Nycomed Deutschland GmbH
Cologne, 50931
Nycomed Deutschland GmbH
Cologne, 50937
Nycomed Deutschland GmbH
Cologne, 50996
Nycomed Deutschland GmbH
Cologne, 51061
Nycomed Deutschland GmbH
Cologne, 51063
Nycomed Deutschland GmbH
Cottbus, 03050
Nycomed Deutschland GmbH
Crimmitschau, 08451
Nycomed Deutschland GmbH
Darmstadt, 64287
Nycomed Deutschland GmbH
Deggendorf, 94469
Nycomed Deutschland GmbH
Deggingen, 73326
Nycomed Deutschland GmbH
Dessau, 06844
Nycomed Deutschland GmbH
Dessau, 06846
Nycomed Deutschland GmbH
Dillingen, 66763
Nycomed Deutschland GmbH
Dillingen, 89407
Nycomed Deutschland GmbH
Dinslaken, 46535
Nycomed Deutschland GmbH
Dommitzsch, 04880
Nycomed Deutschland GmbH
Dörentrup, 32694
Nycomed Deutschland GmbH
Dornstetten, 72280
Nycomed Deutschland GmbH
Dorsten, 46284
Nycomed Deutschland GmbH
Dortmund, 44135
Nycomed Deutschland GmbH
Dortmund, 44388
Nycomed Deutschland GmbH
Dresden, 01099
Nycomed Deutschland GmbH
Dresden, 01187
Nycomed Deutschland GmbH
Dresden, 01307
Nycomed Deutschland GmbH
Duisburg, 47137
Nycomed Deutschland GmbH
Duisburg, 47198
Nycomed Deutschland GmbH
Düren, 52349
Nycomed Deutschland GmbH
Düsseldorf, 40211
Nycomed Deutschland GmbH
Düsseldorf, 40217
Nycomed Deutschland GmbH
Düsseldorf, 40231
Nycomed Deutschland GmbH
Düsseldorf, 40237
Nycomed Deutschland GmbH
Düsseldorf, 40489
Nycomed Deutschland GmbH
Eberswalde, 16225
Nycomed Deutschland GmbH
Eggenfelden, 84307
Nycomed Deutschland GmbH
Ehra-Lessien, 38468
Nycomed Deutschland GmbH
Ehrenkirchen, 79238
Nycomed Deutschland GmbH
Einbeck, 37574
Nycomed Deutschland GmbH
Eisenach, 99817
Nycomed Deutschland GmbH
Ellerstadt, 67158
Nycomed Deutschland GmbH
Ellrich, 99755
Nycomed Deutschland GmbH
Ellwangen (Jagst), 73479
Nycomed Deutschland GmbH
Emsdetten, 48282
Nycomed Deutschland GmbH
Emskirchen, 91448
Nycomed Deutschland GmbH
Ennepetal, 58256
Nycomed Deutschland GmbH
Erfde, 24803
Nycomed Deutschland GmbH
Erfurt, 99084
Nycomed Deutschland GmbH
Erfurt, 99086
Nycomed Deutschland GmbH
Erfurt, 99089
Nycomed Deutschland GmbH
Erfurt, 99099
Nycomed Deutschland GmbH
Erlangen, 91052
Nycomed Deutschland GmbH
Eschau, 63863
Nycomed Deutschland GmbH
Eschwege, 37269
Nycomed Deutschland GmbH
Eschweiler, 52249
Nycomed Deutschland GmbH
Essen, 45127
Nycomed Deutschland GmbH
Essen, 45131
Nycomed Deutschland GmbH
Essen, 45279
Nycomed Deutschland GmbH
Essen, 45307
Nycomed Deutschland GmbH
Essen, 45329
Nycomed Deutschland GmbH
Essen, 45355
Nycomed Deutschland GmbH
Essen, 45357
Nycomed Deutschland GmbH
Essenheim, 55270
Nycomed Deutschland GmbH
Esslingen am Neckar, 73734
Nycomed Deutschland GmbH
Ettlingen, 76275
Nycomed Deutschland GmbH
Eutin, 23701
Nycomed Deutschland GmbH
Falkensee, 14612
Nycomed Deutschland GmbH
Feldberger Seenlandschaft, 17258
Nycomed Deutschland GmbH
Flensburg, 24937
Nycomed Deutschland GmbH
Flöha, 09557
Nycomed Deutschland GmbH
Frankenthal, 67227
Nycomed Deutschland GmbH
Frankfurt, 15230
Nycomed Deutschland GmbH
Frankfurt, 15232
Nycomed Deutschland GmbH
Frankfurt, 60389
Nycomed Deutschland GmbH
Frankfurt, 60487
Nycomed Deutschland GmbH
Frankfurt, 60528
Nycomed Deutschland GmbH
Frankfurt am Main, 60596
Nycomed Deutschland GmbH
Freising, 85354
Nycomed Deutschland GmbH
Friedrichshafen, 88046
Nycomed Deutschland GmbH
Friedrichshafen, 88048
Nycomed Deutschland GmbH
Fulda, 36039
Nycomed Deutschland GmbH
Fürstenfeldbruck, 82256
Nycomed Deutschland GmbH
Fürstenwalde, 15517
Nycomed Deutschland GmbH
Fürth, 90762
Nycomed Deutschland GmbH
Fürth, 90766
Nycomed Deutschland GmbH
Ganderkesee, 27777
Nycomed Deutschland GmbH
Gardelegen, 39638
Nycomed Deutschland GmbH
Garmisch-Partenkirchen, 82467
Nycomed Deutschland GmbH
Gauting, 82131
Nycomed Deutschland GmbH
Gelsenkirchen, 45879
Nycomed Deutschland GmbH
Gelsenkirchen, 45881
Nycomed Deutschland GmbH
Gelsenkirchen, 45891
Nycomed Deutschland GmbH
Gelsenkirchen, 45894
Nycomed Deutschland GmbH
Gelsenkirchen, 45897
Nycomed Deutschland GmbH
Gemünden, 97737
Nycomed Deutschland GmbH
Germering, 82110
Nycomed Deutschland GmbH
Gifhorn, 38518
Nycomed Deutschland GmbH
Gladbeck, 45966
Nycomed Deutschland GmbH
Gladbeck, 45968
Nycomed Deutschland GmbH
Glauchau, 08371
Nycomed Deutschland GmbH
Goch, 47574
Nycomed Deutschland GmbH
Gotha, 99867
Nycomed Deutschland GmbH
Gräfenhainichen, 06773
Nycomed Deutschland GmbH
Grebenstein, 34393
Nycomed Deutschland GmbH
Grefrath, 47929
Nycomed Deutschland GmbH
Greiz, 07973
Nycomed Deutschland GmbH
Grimmen, 18507
Nycomed Deutschland GmbH
Grömitz, 23743
Nycomed Deutschland GmbH
Groß Kreutz, 14550
Nycomed Deutschland GmbH
Großaitingen, 86845
Nycomed Deutschland GmbH
Großefehn, 26629
Nycomed Deutschland GmbH
Großkorbetha, 06688
Nycomed Deutschland GmbH
Großschirma, 09603
Nycomed Deutschland GmbH
Gütersloh, 33330
Nycomed Deutschland GmbH
Hagen, 58089
Nycomed Deutschland GmbH
Hagen, 58095
Nycomed Deutschland GmbH
Hagen, 58135
Nycomed Deutschland GmbH
Haibach, 63808
Nycomed Deutschland GmbH
Halbe, 15757
Nycomed Deutschland GmbH
Halberstadt, 38820
Nycomed Deutschland GmbH
Halle, 06108
Nycomed Deutschland GmbH
Halle, 06110
Nycomed Deutschland GmbH
Halle, 06114
Nycomed Deutschland GmbH
Halle, 06132
Nycomed Deutschland GmbH
Halle, 33790
Nycomed Deutschland GmbH
Halstenbek, 25469
Nycomed Deutschland GmbH
Hamburg, 20255
Nycomed Deutschland GmbH
Hamburg, 20354
Nycomed Deutschland GmbH
Hamburg, 20359
Nycomed Deutschland GmbH
Hamburg, 20537
Nycomed Deutschland GmbH
Hamburg, 21029
Nycomed Deutschland GmbH
Hamburg, 22041
Nycomed Deutschland GmbH
Hamburg, 22299
Nycomed Deutschland GmbH
Hamburg, 22527
Nycomed Deutschland GmbH
Hamburg, 22767
Nycomed Deutschland GmbH
Hammelburg, 97762
Nycomed Deutschland GmbH
Hannoversch Münden, 34346
Nycomed Deutschland GmbH
Hanover, 30161
Nycomed Deutschland GmbH
Hanover, 30163
Nycomed Deutschland GmbH
Hanover, 30173
Nycomed Deutschland GmbH
Hanover, 30449
Nycomed Deutschland GmbH
Hanover, 30625
Nycomed Deutschland GmbH
Haren, 49733
Nycomed Deutschland GmbH
Hartha, 04746
Nycomed Deutschland GmbH
Haselünne, 49740
Nycomed Deutschland GmbH
Haßloch, 67454
Nycomed Deutschland GmbH
Heidelberg, 69115
Nycomed Deutschland GmbH
Heilbronn, 74072
Nycomed Deutschland GmbH
Heilbronn, 74080
Nycomed Deutschland GmbH
Heiligenhafen, 23774
Nycomed Deutschland GmbH
Heiligenhaus, 42579
Nycomed Deutschland GmbH
Heimbuchenthal, 63872
Nycomed Deutschland GmbH
Hemmingen, 30966
Nycomed Deutschland GmbH
Herbsleben, 99955
Nycomed Deutschland GmbH
Herne, 44623
Nycomed Deutschland GmbH
Herne, 44629
Nycomed Deutschland GmbH
Herne, 44649
Nycomed Deutschland GmbH
Herne, 44651
Nycomed Deutschland GmbH
Herzlake, 49770
Nycomed Deutschland GmbH
Hettstedt, 06333
Nycomed Deutschland GmbH
Hille, 32429
Nycomed Deutschland GmbH
Höchstadt an der Aisch, 91315
Nycomed Deutschland GmbH
Hohenmölsen, 06679
Nycomed Deutschland GmbH
Homberg (Ohm), 34576
Nycomed Deutschland GmbH
Homburg, 66424
Nycomed Deutschland GmbH
Horb, 72160
Nycomed Deutschland GmbH
Hoyerswerda, 02977
Nycomed Deutschland GmbH
Ibbenbueren, 49477
Nycomed Deutschland GmbH
Idstein, 65510
Nycomed Deutschland GmbH
Illerrieden, 89186
Nycomed Deutschland GmbH
Iserlohn, 58636
Nycomed Deutschland GmbH
Issum, 47661
About this study
Official title: Daxas for COPD Therapy (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum. As COPD progresses, patients experience increasing deterioration of their health-related quality of life, with greater impairment in their ability to work and declining participation in social and physical activities.
The aim of this non-interventional study is to evaluate data on quality of life in COPD patients in Germany in a real life medical setting under therapy with the phosphodiesterase-inhibitor (PDE-4) roflumilast (Daxas). Evaluation is based on two COPD specific questionnaires to assess the patient's health status over six months. During the study, lung function measurements such as spirometry will be conducted according to common medical standard. Daxas (tablet) will be administered once daily. The study will provide further data on the safety and tolerability of Daxas.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Being tested
- Daxas
- Keywords
- COPD, Quality of life, lung function, spirometry, roflumilast, Daxas, severe COPD
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DaxasDrug
500 microgram, oral, once daily as add-on therapy to existing therapy
| Study group | Role | What they receive |
|---|---|---|
| DACOTA | Not described Receives: Drug: Daxas |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pre-/post comparison of the COPD status based on patients health status
Evaluation of treatment success by a COPD-specific patient questionnaire
Measured: after 6 months
Secondary outcomes (4)
Effectiveness during treatment
Evaluation of treatment success by a health status patient questionnaire
Measured: after 6 months
Pre-/post comparison of spirometry data
Measured: after 6 months
Evaluation of tolerability
assessment of adverse drug reactions
Measured: after 6 months
Evaluation of symptom reduction of sputum and cough
Measured: after 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2011 (estimated)
- Study startAug 2010
- Primary completionFeb 2012
- Study completionFeb 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,645 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AstraZeneca AstraZeneca, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01285167
- Sponsor's protocol ID
- RO-2455-401-DE
- Other IDs
- U1111-1136-8784
- Acronym
- DACOTA
- Status last verified
- Sep 2016
- First submitted
- 21 Jan 2011
- Last updated
- 31 Oct 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Daxas for COPD Therapy (DACOTA)
- ClinicalTrials.gov ID
- NCT01285167
- Acronym / sponsor ID
- DACOTA / RO-2455-401-DE
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- COPD, Quality of life, lung function, spirometry, roflumilast, Daxas, severe COPD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,645 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Aug 2010
- Primary completion
- Feb 2012 (actual)
- Study completion
- Feb 2012 (actual)
- First posted
- 27 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum. As COPD progresses, patients experience increasing deterioration of their health-related quality of life, with greater impairment in their ability to work and declining participation in social and physical activities.
The aim of this non-interventional study is to evaluate data on quality of life in COPD patients in Germany in a real life medical setting under therapy with the phosphodiesterase-inhibitor (PDE-4) roflumilast (Daxas). Evaluation is based on two COPD specific questionnaires to assess the patient's health status over six months. During the study, lung function measurements such as spirometry will be conducted according to common medical standard. Daxas (tablet) will be administered once daily. The study will provide further data on the safety and tolerability of Daxas.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| DACOTA | – | Drug: Daxas |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients diagnosed with severe COPD.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Daxas500 microgram, oral, once daily as add-on therapy to existing therapy | Drug | DACOTA |
Primary outcome
Pre-/post comparison of the COPD status based on patients health status
Time frame: after 6 months
Evaluation of treatment success by a COPD-specific patient questionnaire
4 secondary outcomes
Effectiveness during treatment
Time frame: after 6 months
Pre-/post comparison of spirometry data
Time frame: after 6 months
Evaluation of tolerability
Time frame: after 6 months
Evaluation of symptom reduction of sputum and cough
Time frame: after 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2016.
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AstraZeneca AstraZeneca study director
AstraZeneca
605 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease, run by AstraZeneca at 605 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 605 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pre-/post comparison of the COPD status based on patients health status (time frame: after 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2016.